Literature DB >> 9544733

Dietary L-arginine decreases myointimal cell proliferation and vascular monocyte accumulation in cholesterol-fed rabbits.

R H Böger1, S M Bode-Böger, S Kienke, A C Stan, R Nafe, J C Frölich.   

Abstract

L-arginine, the precursor of endogenous nitric oxide (NO), has been shown to enhance endothelial function and to reduce the progression of atherosclerosis in cholesterol-fed rabbits. In the present study, we investigated whether myointimal cell proliferation is enhanced in hypercholesterolaemic rabbit aorta and whether chronic treatment of the rabbits with L-arginine or with the NO synthase inhibitor L-NAME influences this proliferative response and vascular monocyte accumulation. Rabbits were fed 1% cholesterol or normal rabbit chow for 12 weeks. Subgroups of cholesterol-fed rabbits were treated with oral L-arginine (2.25%) or L-NAME (3 mg/dl) in drinking water. Myointimal cell proliferation was quantified in aortic segments by immunohistochemical detection of bromodeoxyuridine (BrdU) incorporation into nuclear DNA; vascular monocyte accumulation was assessed by immunohistochemistry using a monoclonal anti-macrophage/monocyte antibody (RAM-11). Plasma levels of L-arginine and the endogenous NO synthase inhibitor, ADMA, were quantified by high-performance liquid chromatography (HPLC). Cholesterol feeding increased the aortic intima/media (I/M) ratio, which was not measurable in the control group, to 1.9 +/- 0.3. This was paralleled by enhanced cell proliferation (cholesterol, 2.4 +/- 0.2%; P < 0.05; control, 0.02 +/- 0.001% BrdU-positive cells per 72 h) and vascular monocyte accumulation. Double immunostaining for BrdU and alpha-actin showed that about two thirds of the proliferating cells were smooth muscle cells. ADMA levels increased from 0.8 +/- 0.1 micromol/l to 2.2 +/- 0.2 micromol/l in cholesterol-fed rabbits, but were unchanged by L-arginine or L-NAME treatment. Myointimal proliferation and intima/media ratios were correlated with ADMA plasma levels. Dietary L-arginine reduced monocyte accumulation by 85 +/- 2% (P < 0.05 vs cholesterol), myointimal cell proliferation (1.8 +/- 0.3% per 72 h; P < 0.05) and intimal thickening (I/M ratio: 0.7 +/- 0.2), whereas the inhibitor of NO synthase, L-NAME, further increased cell proliferation to 3.1 +/- 0.4% per 72 h (P < 0.05). No significant difference was observed in vascular monocyte infiltration between the cholesterol and L-NAME groups. We conclude that cell proliferation and vascular monocyte accumulation are enhanced in hypercholesterolaemic rabbit aorta. These atherogenic effects can be attenuated by dietary L-arginine. Decreased NO formation might underlie the enhanced monocyte accumulation and cell proliferation in hypercholesterolaemic rabbit aorta. The observed inhibition of cell proliferation adds to our understanding of the antiatherosclerotic effects of L-arginine in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9544733     DOI: 10.1016/s0021-9150(97)00183-4

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  16 in total

1.  l-Citrulline and l-arginine supplementation retards the progression of high-cholesterol-diet-induced atherosclerosis in rabbits.

Authors:  Toshio Hayashi; Packiasamy A R Juliet; Hisako Matsui-Hirai; Asaka Miyazaki; Akiko Fukatsu; Jun Funami; Akihisa Iguchi; Louis J Ignarro
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-12       Impact factor: 11.205

2.  Oral supplement of six selective amino acids arrest progression renal failure in uremic patients.

Authors:  Hippocrates Yatzidis
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

3.  Asymmetric Dimethylarginine Predicts One-year Recurrent Cardiovascular Events: Potential Biomarker of "Toxin Syndrome" in Coronary Heart Disease.

Authors:  Hao Xu; Zhuo Chen; Qing-Hua Shang; Zhu-Ye Gao; Chang-An Yu; Da-Zhuo Shi; Ke-Ji Chen
Journal:  Chin J Integr Med       Date:  2019-05-07       Impact factor: 1.978

Review 4.  Current, new and future treatments in dyslipidaemia and atherosclerosis.

Authors:  P H Chong; B S Bachenheimer
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

5.  The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease.

Authors:  Latika Sibal; Sharad C Agarwal; Philip D Home; Rainer H Boger
Journal:  Curr Cardiol Rev       Date:  2010-05

Review 6.  Role of oxidative stress and nitric oxide in atherothrombosis.

Authors:  Edith Lubos; Diane E Handy; Joseph Loscalzo
Journal:  Front Biosci       Date:  2008-05-01

7.  Receptor-mediated activation of nitric oxide synthesis by arginine in endothelial cells.

Authors:  Mahesh S Joshi; T Bruce Ferguson; Fruzsina K Johnson; Robert A Johnson; Sampath Parthasarathy; Jack R Lancaster
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-29       Impact factor: 11.205

8.  Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease.

Authors:  Insa E Emrich; Adam M Zawada; Jens Martens-Lobenhoffer; Danilo Fliser; Stefan Wagenpfeil; Gunnar H Heine; Stefanie M Bode-Böger
Journal:  Clin Res Cardiol       Date:  2017-11-03       Impact factor: 5.460

9.  Relationship between cerebral arterial pulsatility and carotid intima media thickness in diabetic and non-diabetic patients with non-alcoholic fatty liver disease.

Authors:  F Karakurt; A Carlioglu; A Koktener; M Ozbek; A Kaya; M E Uyar; B Kasapoglu; A Ilhan
Journal:  J Endocrinol Invest       Date:  2009-01       Impact factor: 4.256

10.  Strategies and methods to study sex differences in cardiovascular structure and function: a guide for basic scientists.

Authors:  Virginia M Miller; Jay R Kaplan; Nicholas J Schork; Pamela Ouyang; Sarah L Berga; Nanette K Wenger; Leslee J Shaw; R Clinton Webb; Monica Mallampalli; Meir Steiner; Doris A Taylor; C Noel Bairey Merz; Jane F Reckelhoff
Journal:  Biol Sex Differ       Date:  2011-12-12       Impact factor: 5.027

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.